Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000077.xml
Semin Thromb Hemost 2000; Volume 26(Number s1): 061-068
DOI: 10.1055/s-2000-9495
DOI: 10.1055/s-2000-9495
Low-Molecular-Weight Heparin in the Treatment of Venous Thromboembolism
Further Information
Publication History
Publication Date:
31 December 2000 (online)
ABSTRACT
The low-molecular-weight heparins (LMWHs) have been evaluated in the prevention and treatment of deep-vein thrombosis and pulmonary embolism. LMWHs have been found to be safe and effective in this clinical setting and have advantages over unfractionated heparin. These advantages include less serious and less frequent therapeutic complications. The favorable pharmacokinetic profile of LMWHs compared with heparin has allowed for safe, effective, and convenient treatment of patients with venous thromboembolism. Use of LMWHs ultimately results in considerable cost savings for the health care system.
KEYWORD
Low-molecular-weight heparin - tinzaparin - thromboprophylaxis - venous thromboembolism - cost-effectiveness
REFERENCES
- 1 Brandjes D P, Buller H R, Heijboer H. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet . 1997; 349 759-762
- 2 Franzeck U K, Schalch I, Jager K A. Prospective 12-year follow-up study of clinical and hemodynamic sequelae after deep vein thrombosis in low-risk patients (Zurich study). Circulation . 1996; 93 74-79
- 3 Lane D A. Heparin binding and neutralizing protein. In: Lane DA, Lindahl U, eds. Heparin: Chemical and Biological Properties, Clinical
Applications
London: Edward Arnold, 1989: 363-931
MissingFormLabel
- 4 Lindahl U, Thunberg L, Backstrom G. Extension and structural variability of the antithrombin-binding sequence in heparin. J Biol Chem . 1984; 259 12368-12376
- 5 Rosenberg R D, Lam L. Correlation between structure and function of heparin. Proc Natl Acad Sci USA . 1979; 76 1218-1222
- 6 Salzman E W, Rosenberg R D, Smith M H, Lindon J N, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest . 1980; 65 64-73
- 7 Casu B, Oreste P, Torri G. The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Chemical and 13C nuclear-magnetic-resonance studies. Biochem J . 1981; 197 599-609
- 8 Weitz J I, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest . 1990; 86 385-391
- 9 Tollefsen D M, Majerus D W, Blank M K. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem . 1982; 257 2162-2169
- 10 Hoppensteadt D A, Walenga J M, Fasanella A, Jeske W, Fareed J. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Thromb Res . 1995; 77 175-185
- 11 Blajchman M A, Young E, Ofosu F A. Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits. Ann N Y Acad Sci . 1989; 556 245-254
- 12 Gallus A, Jackaman J, Tillett J, Mills W, Wycherley A. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet . 1986; 2 1293-1296
- 13 Hull R D, Raskob G E, Rosenbloom D. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med . 1990; 322 1260-1264
- 14 Hyers T M, Agnelli G, Hull R D. Antithrombotic therapy for venous thromboembolic disease. Chest . 1998; 14(5 suppl) 561S-578S
- 15 Hull R D, Raskob G E, Rosenbloom D. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med . 1992; 152 1589-1595
- 16 Hull R D, Raskob G E, Brant R F, Pineo G F, Valentine K A. Relation between the time to achieve the lower limit of the aPTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med . 1997; 157 2562-2568
- 17 Hull R D, Raskob G E, Brant R F, Pineo G F, Valentine K A. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence. Arch Intern Med . 1997; 157 2317-2321
- 18 Anand S, Ginsberg J S, Kearon C, Gent M, Hirsh J. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Arch Intern Med . 1996; 156 1677-1681
- 19 Campbell N R, Hull R D, Brant R. Aging and heparin-related bleeding. Arch Intern Med . 1996; 156 857-860
- 20 White R H, Zhou H, Woo L, Mungall D. Effect of weight, sex, age, clinical diagnosis, and thromboplastin reagent on steady-state intravenous heparin requirements. Arch Intern Med . 1997; 157 2468-2472
- 21 Fennerty A, Thomas P, Backhouse G. Audit of control of heparin treatment. BMJ . 1985; 290 27-28
- 22 Wheeler A P, Jaquiss R D, Newman J H. Physician practices in the treatment of pulmonary embolism and deep venous thrombosis. Arch Intern Med . 1988; 148 1321-1325
- 23 Raschke R A, Reilly B M, Guidry J R, Fontana J R, Srinivas S. The weight-based heparin dosing nomogram compared with a ``standard care'' nomogram. Ann Intern Med . 1993; 119 874-881
- 24 Hirsh J, Warkentin T E, Raschke R. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest . 1998; 114(5 suppl) 489S-510S
- 25 Kelton J G. Heparin-induced thrombocytopenia. Haemostasis . 1986; 16 173-186
- 26 Greinacher A, Michel I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost . 1991; 66 734-736
- 27 Boshkov L K, Warkentin T E, Hayward C P, Andrew M, Kelton J G. Heparin-induced thrombocytopenia and thrombosis: Clinical and laboratory studies. Br J Haematol . 1993; 84 322-328
- 28 Magnani H N. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with orgaran. Thromb Haemost . 1993; 70 554-561
- 29 Arepally G, Reynolds C, Tomaski A. Comparison of PF4/heparin ELISA assay with the (14C) serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol . 1995; 104 648-654
- 30 Warkentin T E, Levine M N, Hirsh J. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med . 1995; 332 1330-1335
- 31 Warkentin T E, Chong B H, Greinacher A. Heparin-induced thrombocytopenia: Towards consensus. Thromb Haemost . 1998; 79 1-7
- 32 Hull R D, Raskob G E, Pineo G F. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med . 1992; 326 975-982
- 33 Greinacher A, Volpel H, Janssens U. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study. Circulation . 1999; 99 73-80
- 34 Matsuo T, Kario K, Chikahira Y, Nakao K, Yamada T. Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor. Br J Haematol . 1992; 82 627-629
- 35 Hirsh J, Levine M N. Low molecular weight heparin. Blood . 1992; 79 1-17
- 36 Fareed J, Walenga J M, Hoppensteadt D, Huan X, Racanelli A. Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins. Haemostasis . 1988; 18(suppl 3) 3-15
- 37 Bara L, Samama M. Pharmacokinetics of low molecular weight heparins. Acta Chir Scand . 1988; 543 65-72
- 38 Briant L, Caranobe C, Saivin S. Unfractionated heparin and CY 216: pharmacokinetics and bioavailabilities of the antifactor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit. Thromb Haemost . 1989; 61 348-353
- 39 Andersson L O, Barrowcliffe T W, Holmer E, Johnson E A, Soderstrom G. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. Thromb Res . 1979; 15 531-541
- 40 Fareed J, Walenga J M, Racanelli A. Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparins. Haemostasis . 1988; 18(suppl) 33-47
- 41 Barrowcliffe T W, Curtis A D, Johnson E A, Thomas D P. An international standard for low molecular weight heparin. Thromb Haemost . 1988; 60 1-7
- 42 Holmer E, Soderberg K, Bergqvist D, Lindahl U. Heparin and its low molecular weight derivatives: Anticoagulant and antithrombotic properties. Haemostastis . 1986; 16(suppl 2) 1-7
- 43 Carter C J, Kelton J G, Hirsh J. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood . 1982; 59 1239-1245
- 44 Cade J F, Buchanan M R, Boneu B. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb Res . 1984; 35 613-625
- 45 Andriuoli G, Mastacchi R, Barbanti M, Sarret M. Comparison of the antithrombotic and haemorrhagic effects of heparin and a new low molecular weight heparin in rats. Haemostasis . 1985; 15 324-330
- 46 Lensing A W, Prins M H, Davidson B L, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med . 1995; 155 601-607
- 47 Monreal M, Lafoz E, Salvador R, Roncales J, Navarro A. Adverse effects of three different forms of heparin therapy: Thrombocytopenia, increased transaminases, and hyperkalaemia. Eur J Clin Pharmacol . 1989; 37 415-418
- 48 Monreal M, Vinas L, Monreal L. Heparin-related osteoporosis in rats. A comparative study between unfractionated heparin and a low-molecular-weight heparin. Haemostasis . 1990; 20 204-207
- 49 Matzsch T, Bergqvist D, Hedner U, Nilsson B, Ostergaard P. Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats. Thromb Haemost . 1990; 63 505-509
- 50 Shaughnessy S G, Young E, Deschamps P, Hirsh J. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood . 1995; 86 1368-1373
- 51 Warkentin T E, Levine M N, Hirsh J. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med . 1995; 332 1374-1376
- 52 Forestier F, Daffos F, Capella-Pavlovsky M. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy study by direct fetal blood sampling under ultrasound. Thromb Res . 1984; 34 557-560
- 53 Omri A, Delaloye F J, Andersen H, Bachmann F. Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy. Thromb Haemost . 1989; 61 55-56
- 54 Wahlberg T B, Kher A. Low molecular weight heparin as thromboprophylaxis in pregnancy. A retrospective analysis from 14 European clinics. Haemostasis . 1994; 24 55-56
- 55 Dulitzki M, Pauzner R, Langevitz P. Low-molecular-weight heparin during pregnancy and delivery: Preliminary experience with 41 pregnancies. Obstet Gynecol . 1996; 87 380-383
- 56 Nelson-Piercy C, Letsky E A, De Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: Experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol. 1997; 176 1062-1068
- 57 Hunt B J, Doughty H A, Majumdar G. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost . 1997; 77 39-43
- 58 Sanson B J, Lensing A W, Prins M H. Safety of low-molecular-weight heparin in pregnancy: A systematic review. Thromb Haemost . 1999; 81 668-672
- 59 Ginsberg J S, Hirsh J. Use of antithrombotic agents during pregnancy. Chest . 1998; 114(5 suppl) 524S-530S
- 60 Bratt G, Tornebohm E, Granqvist S, Aberg W, Lockner D. A comparison between low molecular weight heparin (KABI 2165) standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemost. 1985; 54 813-817
- 61 Holm H A, Ly B, Handeland G F. Subcutaneous heparin treatment of deep venous thrombosis: A comparison of unfractionated low molecular weight heparin. Haemostasis. 1986; 16(suppl 2) 30-37
- 62 Albada J, Nieuwenhuis H K, Sixma J J. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin): Results of a double-blind randomized study. Circulation . 1989; 80 935-940
- 63 Bratt G, Aberg W, Johansson M. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (deep vein thrombosis). Thromb Haemost . 1990; 64 506-510
- 64 Harenberg J, Huck K, Bratsch H. Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis. Haemostasis . 1990; 20(suppl 1) 205-219
- 65 Siegbahn A, Y-Hassan S, Boberg J. Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-Novo. Thromb Res . 1989; 55 767-778
- 66 Prandoni P, Lensing A W, Buller H R. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet . 1992; 339 441-445
- 67 Lopaciuk S, Meissner A J, Filipecki S. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: A Polish multicenter trial. Thromb Haemost . 1992; 68 14-18
- 68 Simonneau G, Charbonnier B, Decousus H. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med . 1993; 153 1541-1546
- 69 Lindmarker P, Holmstrom M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost . 1994; 72 186-190
- 70 Levine M, Gent M, Hirsh J. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med . 1996; 334 677-681
- 71 Koopman M MW, Prandoni P, Piovella F. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med . 1996; 334 682-687
- 72 The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med . 1997; 337 657-662
- 73 Simonneau G, Sors H, Charbonnier B. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med . 1997; 337 663-669
- 74 Decousus H, Leizorovicz A, Parent F. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. New Engl J Med . 1998; 338 409-415
- 75 Hettiarchichi R JK, Prins M H, Lensing A W, Buller H R. Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism. Curr Opin Pulm Med . 1998; 4 220-225
- 76 Green D, Hull R D, Brant R, Pineo G F. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet . 1992; 339 1476 ((Letter))
- 77 Hull R D, Raskob G E, Rosenbloom D. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. Arch Intern Med . 1997; 157 289-294
- 78 van den Belt G A, Bossuyt P M, Prins M H, Gallus A S, Buller H R, for the TASMAN Study Group. Replacing in-patient care by out-patient care in the treatment of deep venous thrombosis-an economic evaluation. Thromb Haemost . 1998; 79 259-263
- 79 Wells P S, Kovacs M J, Bormanis J. Expanding eligibility for out-patient treatment of deep venous thrombosis pulmonary embolism with low-molecular-weight heparin: A comparison of patient self-injection with homecare injection. Arch Intern Med . 1998; 158 1809-1812
- 80 Harrison L, McGinnis J, Crowther M, Ginsberg J, Hirsh J. Assessment of out-patient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med . 1998; 158 2001-2003
- 81 Savage K J, Wells P S, Schulz V. Outpatient use of low molecular weight heparin (dalteparin) for the treatment of deep vein thrombosis of the upper extremity. Thromb Haemost . 1999; 82 1008-1010
- 82 Hull R D, Raskob G E, Brant R F. Low-molecular-weight heparin versus heparin in the treatment of patients with pulmonary embolism. Arch Intern Med . 2000; 160 229-236
- 83 Fiessinger J N, Lopez-Fernandez M, Gatterer E. Once-daily subcutaneous dalteparin, a low molecular weight heparin for the initial treatment of acute deep vein thrombosis. Thromb Haemost. 1996; 76 195-199
- 84 Spiro T E. Clinical use of low molecular weight heparins. Thromb Haemost . 1997; 1527 373
- 85 Charbonnier B A, Fiessinger J N, Banga J D. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. Thromb Haemost . 1998; 79 897-901